Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

• Market Cap: ₹79.90B
• Dividend Yield: 3.28%
• Average Volume (3M): 310.00
• Price to Earnings (P/E): 30.5
• Beta (1Y): 0.57
• Revenue Growth: 3.01%
• EPS Growth: 22.98%
• Country: IN
• Employees: 1,336
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 16,599,382
• 10 Day Avg. Volume: 340
• 30 Day Avg. Volume: 310
• PEG Ratio: 1.37
• Price to Book (P/B): 15.96
• Price to Sales (P/S): 7.03
• P/FCF Ratio: 51.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹6,800.00
• Price Target Upside: 18.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 219
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ₹5,363.00 ▼(-6.76% Downside)
• Action: Reiterated Date: 10/21/25
• Date: Action: Reiterated 10/21/25

Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates mixed signals with short-term bearish momentum but a long-term bullish trend. The valuation is slightly high, reflecting growth expectations, but the attractive dividend yield provides a buffer. The absence of earnings call data and corporate events does not impact the score.

Positive Factors

Balance sheet strength

Extremely low leverage and a very high ROE indicate durable financial stability and efficient capital use. Minimal debt reduces refinancing and interest risk, while strong equity returns provide sustained capacity to fund growth, distributions, or M&A without stressing the balance sheet.

Negative Factors

Cost pressure on gross margin

A slipping gross margin signals rising input or manufacturing costs that could erode long-term profitability if not offset by pricing or efficiency gains. Sustained cost pressures would force margin trade-offs or require structural cost reductions to protect earnings power.

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasi...

Read more

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasi...

How the Company Makes Money

null...

Procter & Gamble Health Ltd. Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	12.84B	12.18B	11.51B	12.30B	11.14B	10.09B
Gross Profit	8.88B	8.69B	8.09B	8.46B	7.61B	6.84B
EBITDA	4.20B	3.62B	3.03B	3.19B	2.65B	2.42B
Net Income	3.07B	2.51B	2.01B	2.29B	1.93B	1.77B
Balance Sheet
Total Assets	8.94B	7.94B	7.94B	11.01B	8.94B	9.86B
Cash, Cash Equivalents and Short-Term Investments	2.86B	1.89B	2.44B	4.53B	3.19B	4.64B
Total Debt	95.50M	76.20M	95.60M	120.00M	28.30M	76.10M
Total Liabilities	2.75B	2.57B	2.56B	3.50B	2.77B	2.82B
Stockholders Equity	6.20B	5.37B	5.38B	7.51B	6.16B	7.04B
Cash Flow
Free Cash Flow	2.12B	1.67B	2.07B	1.94B	1.32B	1.95B
Operating Cash Flow	2.21B	1.76B	2.28B	2.36B	1.70B	2.47B
Investing Cash Flow	13.60M	24.40M	-68.70M	-215.00M	-255.40M	-322.70M
Financing Cash Flow	-2.10B	-2.35B	-4.18B	-984.70M	-2.89B	-3.87B

Procter & Gamble Health Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5751.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Negative. The current price of 5751.7 is above the 20-day moving average (MA) of 4859.46, above the 50-day MA of 5069.78, and above the 200-day MA of 5746.88, indicating a bearish trend. The MACD of -75.25 indicates Negative momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 27.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGHL	73 Outperform	₹79.90B	30.50	―	3.28%	3.01%	22.98%
SYMPHONY	70 Outperform	₹49.35B	73.49	―	1.43%	-19.72%	-44.03%
SURYAROSNI	70 Outperform	₹45.45B	18.80	―	2.03%	0.31%	1.98%
ZYDUSWELL	66 Neutral	₹157.74B	-90.62	―	0.28%	14.55%	-20.61%
JYOTHYLAB	64 Neutral	₹78.33B	31.99	―	1.24%	1.62%	-7.32%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
EVEREADY	55 Neutral	₹20.36B	80.19	―	0.46%	7.37%	-39.19%

Procter & Gamble Health Ltd. Corporate Events